Shandong Wohua Pharmaceutical (002107.SZ) announced its performance forecast for the first half of 2024, with a net income of 8.9 million yuan to 13.2 million yuan attributable to shareholders of listed companies, a decrease of 76.08%-64.52% compared to the same period last year; net income of 8.2 million yuan to 12 million yuan after deducting non-recurring gains and losses, a decrease of 77.02%-66.38% compared to the same period last year; and basic earnings per share of 0.0154 yuan/share - 0.0229 yuan/share.

The company's core product, Chinese patent medicine Wo Hua Xin Ke Shu Tablet, was selected by the National Chinese Patent Medicine Procurement Alliance for centralized quantity procurement in June 2023, with a winning bid price about 39% lower than the original price. In this reporting period, Wo Hua Xin Ke Shu Tablet was sold at the centralized procurement price, resulting in a reduction of sales revenue, gross profit contribution, and operating profit.